„At Unified Health, we believe in providing our patients with exceptional medical care and access to the most advance medical technology. Our experienced team of providers are committed to delivering the highest quality of dermatological care to our patients, especially when it comes to the earliest detection possible of melanoma – the deadliest form of… SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order weiterlesen
We are pleased to announce the election of Jesper Høiland as the new Chairman of the Board. Jesper has over 25 years of experience from senior positions in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US with a particular focus on pricing, product… SciBase welcomes new chairman and thanks the former weiterlesen
SciBase is pleased to announce that Leda will be heading the US commercial operations. With an extensive background in sales and commercialization across pharmaceutical, medical devices and biotechnology she brings over 27 years of experience to this pivotal role. Leda joins from DermTech Inc., a skin cancer detection company, where she was Senior National Director,… SciBase strengthens the US organization with experienced leader in dermatology weiterlesen
Terms and conditions for warrants of series TO 2 in summaryEach warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company during the period 3 April 2029 up to and including 17 April 2029. The subscription price for subscription of shares with the support of warrants of… Today is the first day of trading in the new shares and warrants of series TO 2 issued in connection with the completed capital raising weiterlesen
SciBase has since the end of the first quarter, following the strong development in Germany, expanded into Austria and Switzerland. In March, a sales representative was hired in Austria with previous experience in establishing businesses in dermatology and he is now responsible for establishing Nevisense in these markets. Nevisense has been presented and demonstrated in… SciBase receives first order in Austria weiterlesen
Researchers of the skin barrier and cosmetic products can now use Nevisense and the eBarrier Score to assess products and claims related to skin barrier function. The global market for cosmetic products aiming to improve people’s skin barrier is experiencing immense growth. Nevisense and the eBarrier Score utilize AI-generated algorithms that researchers can use to… SciBase Announces the launch of eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing weiterlesen
The article is available through the following link: https://jofskin.org/index.php/skin/article/view/2789 „This is a very important study and results for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense even compared to dermsocopy. In Germany dermoscopy is standard of care for Dermatologists. The study showed that the addition of Nevisense further improved dermatologists’ clinical performance.… New German study shows Nevisense significantly improves dermatologists clinical decisions weiterlesen
A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFO Tel: +46 70 341 34 72 E-mail: Certified Advisor: Vator Securities Tel: +46 580 065 99 Email: The… SciBase publishes the Annual report for 2023 weiterlesen
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase announces outcome in the directed issue of units weiterlesen
Amendment of the articles of associationThe general meeting resolved, in accordance with the board of directors‘ three proposals, to amend §§ 4-5 of the articles of association, entailing: that the articles of association shall be amended so that the share capital shall be not less than SEK 10,065,000 and not more than SEK 40,260,000 and… Bulletin from the extraordinary general meeting in SciBase Holding AB (publ) weiterlesen
